financingSenisca Ltd raises £3.7m seed moneyExeter-based university spin-out Senisca Ltd has added £3.7m seed money to a £1.1m not dilutive funding to advance its pipeline of drugs targetting RNA splicing dysregulation. more ➔
acquisitionAstraZeneca to acquire Amolyt Pharma for u...French endocrine diseases specialist Amolyt Pharma SA has entered into a take-over agreement by AstraZeneca. more ➔
financingRelation Therapeutics Ltd bags US$35m in s... London-based virtual drug discovery specialist Relation Therapeutics Ltd has closed another US$35m seed financing round, bringing its total seed fundraise to US$60m. more ➔
atherosclerosisResearcher find potential target for ather...TREM2, a receptor on the surface of macrophages, reduces necrotic core formation in early atherosclerosis, a German-Austrian reseach team reports. more ➔
RNAScientists create non-digestible aptamerGerman researchers for the first time have expanded the half life of oligonucleotide-based drugs using artificial building blocks that mimic the features of RNA/DNA but are not digestible by enzymes … more ➔
rare diseasesSynaptixBio Ltd gets FDA ODD for leukodyst...Rare disease specialist SynaptixBio Ltd has got its second FDA orphan drug designation for a subtype of TUBB4A leukodystrophy. more ➔
cancerPierre Fabre SAS in US$31m licence deal wi...Pierre Fabre Médicament SAS has entered into an Asset Purchase Agreement (APA) over pan-RAF programs developed by Kinnate Biopharma Inc. more ➔
OphtalmologyPulseSight to disrupt AMD spacePulseSight Therapeutics SAS was launched on Wednesday, backed by seed financing from Pureos Bioventures and ND Capital. The company introduces a disruptive delivery platform in ophthalmology biotech, … more ➔
